(NASDAQ: CMPX) Compass Therapeutics's forecast annual revenue growth rate of 389.71% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Compass Therapeutics's revenue in 2025 is $850,000.On average, 1 Wall Street analysts forecast CMPX's revenue for 2025 to be $1,700,874,725, with the lowest CMPX revenue forecast at $1,700,874,725, and the highest CMPX revenue forecast at $1,700,874,725. On average, 7 Wall Street analysts forecast CMPX's revenue for 2026 to be $2,607,593,065, with the lowest CMPX revenue forecast at $374,745,570, and the highest CMPX revenue forecast at $5,437,267,821.
In 2027, CMPX is forecast to generate $14,739,669,744 in revenue, with the lowest revenue forecast at $5,351,532,673 and the highest revenue forecast at $31,641,801,192.